{"filing":{"accession_number":"0001104659-26-073593","cik":"0001130598","ticker":"TRAW","company_name":"Traws Pharma, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"tm2617872d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926073593/tm2617872d1_8k.htm"},"events":[{"id":10376,"run_id":9098,"accession_number":"0001104659-26-073593","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The filing discloses deferral of a Phase 2a clinical trial for tivoxavir marboxil due to a negative regulatory review by the UK's Medicines and Healthcare Products Regulatory Agency. This represents a material setback to a key drug development program that would affect investor assessment of the company's pipeline and prospects, but does not fit neatly into the more specific event categories (it is neither a restatement, impairment charge, litigation, nor M\u0026A activity). The regulatory rejection of a planned clinical study is a material development for a pharmaceutical company.","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6676,"accession_number":"0001104659-26-073593","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses deferral of a Phase 2a clinical trial for tivoxavir marboxil due to a negative regulatory review by the UK's Medicines and Healthcare Products Regulatory Agency. This represents a material setback to a key drug development program that would affect investor assessment of the company's pipeline and prospects, but does not fit neatly into the more specific event categories (it is neither a restatement, impairment charge, litigation, nor M\u0026A activity). The regulatory rejection of a planned clinical study is a material development for a pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:06:20.100803+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6676,"accession_number":"0001104659-26-073593","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses deferral of a Phase 2a clinical trial for tivoxavir marboxil due to a negative regulatory review by the UK's Medicines and Healthcare Products Regulatory Agency. This represents a material setback to a key drug development program that would affect investor assessment of the company's pipeline and prospects, but does not fit neatly into the more specific event categories (it is neither a restatement, impairment charge, litigation, nor M\u0026A activity). The regulatory rejection of a planned clinical study is a material development for a pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:06:20.100803+00:00","company_name":"Traws Pharma, Inc.","ticker":"TRAW","filing_date":"2026-06-12"}]}